{{Drugbox
| IUPAC_name = ''N''-[(2''S'')-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide
| image = ADB-CHMINACA-fixed.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = 
| legal_US = Schedule I
| legal_status = Illegal in Singapore, Sweden, Switzerland
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1185887-13-1
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 68894304
| ChemSpiderID      = 48059556
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SL4C60689M
| smiles            = CC(C)(C)[C@H](NC(=O)c1nn(CC2CCCCC2)c3ccccc13)C(N)=O
| StdInChI          = 1S/C21H30N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h7-8,11-12,14,18H,4-6,9-10,13H2,1-3H3,(H2,22,26)(H,23,27)/t18-/m1/s1
| StdInChIKey       = ZWCCSIUBHCZKOY-GOSISDBHSA-N

<!--Chemical data-->
| C=21 | H=30 | N=4 | O=2 
| molecular_weight = 370.24 g/mol
}}

'''ADB-CHMINACA''' (also known as '''MAB-CHMINACA''') is an [[indazole]]-based [[synthetic cannabinoid]]. It is a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] with a binding affinity of ''K''<sub>i</sub>&nbsp;=&nbsp;0.289&nbsp;nM and was originally developed by [[Pfizer]] in 2009 as an [[analgesic]] medication.<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/16616 | title=MAB-CHMINACA | publisher=Cayman Chemical | accessdate=16 June 2015}}</ref><ref>{{cite journal | url=https://www.google.com/patents/WO2009106980A3 | title=Patent WO/2009/106980 - Indazole derivatives}}</ref> It was identified in cannabinoid blends in Japan in early 2015.<ref>{{cite journal | author1=Amin Wurita | url=https://link.springer.com/article/10.1007/s11419-015-0264-y | title=Identification and quantitation of 5-fluoro-ADB-PINACA and MAB-CHMINACA in dubious herbal products | date=July 2015 | author2=Koutaro Hasegawa | author3=Kayoko Minakata | author4=Kunio Gonmori | author5=Hideki Nozawa | author6=Itaru Yamagishi | author7=Kanako Watanabe | author8=Osamu Suzuki | journal=Forensic Toxicology | volume=33 | issue=2 | pages=213–220 | doi=10.1007/s11419-015-0264-y}}</ref>

== Side Effects ==

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.<ref>{{cite journal | author1=Koutaro Hasegawa | url=https://link.springer.com/article/10.1007/s11419-015-0272-y | title=Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver | date=July 2015 | author2=Amin Wurita | author3=Kayoko Minakata | author4=Kunio Gonmori | author5=Hideki Nozawa | author6=Itaru Yamagishi | author7=Kanako Watanabe | author8=Osamu Suzuki | journal=Forensic Toxicology | volume=33 | issue=2 | pages=380–387 | doi=10.1007/s11419-015-0272-y}}</ref><ref>{{cite web | url=https://www.nytimes.com/2015/04/25/health/surge-in-hospital-visits-linked-to-a-drug-called-spice-alarms-health-officials.html | title=Potent ‘Spice’ Drug Fuels Rise in Visits to Emergency Room | publisher=The New York Times | date=24 April 2015 | accessdate=29 June 2015 | author=Alan Schwarz}}</ref><ref>{{cite web | url=http://www.aapcc.org/press/43/ | title=American Association of Poison Control Centers Issues Warning About Reemerging Synthetic Drugs | publisher=American Association of Poison Control Centers | date=23 April 2015 | accessdate=29 June 2015}}</ref><ref>{{cite web | url=http://www.adph.org/news/assets/150511.pdf | title=Synthetic cannabinoid users can exhibit bizarre and  violent behaviors, hospitalizations after use increase in Alabama over  past week | publisher=Alabama Department of Public Health | date=11 May 2015 | accessdate=29 June 2015}}</ref><ref>{{cite web | url=http://www.drugscouts.de/de/pillenwarnung/todesf%C3%A4lle-zusammenhang-mit-adb-chminaca | title=Todesfälle in Zusammenhang mit ADB-CHMINACA | publisher=Drug Scouts | date=7 May 2015 | accessdate=29 June 2015}}</ref><ref>{{cite journal | url=http://www.nejm.org/doi/full/10.1056/NEJMp1505328 | title=Synthetic Cannabinoid–Related Illnesses and Deaths |author1=Jordan Trecki |author2=Roy R. Gerona |author3=Michael D. Schwartz | journal=New England Journal of Medicine |date=July 2015  | volume=373 | issue=2 | pages=103–107 | doi=10.1056/NEJMp1505328 | pmid=26154784}}</ref><ref>{{cite web | url=http://www.huffingtonpost.com/2015/05/08/synthetic-marijuana-hospitalizations_n_7241772.html | title=There's Been A Sudden, Alarming Spike In Hospitalizations Caused By Synthetic Marijuana | publisher=Huffington Post | date=8 May 2015 | accessdate=8 August 2015 | author=Dave Collins}}</ref><ref>{{cite journal | url=http://www.tandfonline.com/doi/abs/10.1080/15563650.2016.1190016 | title=Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA | author=Piotr Adamowicz, Joanna Gieroń | journal=Clinical Toxicology | date=May 2016 | pages=1–5 | doi=10.1080/15563650.2016.1190016 | pmid=27227269 | volume=54}}</ref>

== Legal status ==
As of October 29, 2014 Louisiana placed ADB-CHMINACA into [[List of Schedule I drugs (US)|Schedule I]] by emergency scheduling.<ref>{{cite web | url=http://dhh.louisiana.gov/index.cfm/newsroom/detail/3161 | title=Gov. Jindal and State Officials Ban New Synthetic Marijuana Compound | accessdate=16 June 2015}}</ref>

Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara | publisher=Folkhälsomyndigheten | accessdate=29 June 2015}}</ref>

ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=24 July 2015}}</ref>

The [[Drug Enforcement Administration|DEA]] announced its intent to place ADB-CHMINACA into Schedule I of the USA [[Controlled Substances Act]] on September 16, 2015.<ref>{{cite web | url=https://www.federalregister.gov/articles/2015/09/16/2015-23198/schedules-of-controlled-substances-temporary-placement-of-the-synthetic-cannabinoid-mab-chminaca | title=Schedules of Controlled Substances: Temporary Placement of the Synthetic Cannabinoid MAB-CHMINACA Into Schedule I | publisher=Drug Enforcement Administration | date=16 September 2015 | accessdate=16 September 2015}}</ref>

ADB-CHMINACA is illegal in Switzerland as of December 2015.<ref>{{cite web | url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html | title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien | publisher=Der Bundesrat}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-CHMINACA]]
* [[AB-PINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[MDMB-CHMINACA]]
* [[MDMB-FUBINACA]]
* [[PX-3]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Indazoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazolecarboxamides]]


{{nervous-system-drug-stub}}